Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue

Digestive Diseases and Sciences

Volumn 62, Issue 3, 2017, Pages 678-688

  Levin, Theodore R ^a   Corley, Douglas A ^a   Jensen, Christopher D ^a   Marks, Amy R ^a   Zhao, Wei K ^a   Zebrowski, Alexis M ^b   Quinn, Virginia P ^c   Browne, Lawrence W ^a   Taylor, William R ^d   Ahlquist, David A ^d   Lidgard, Graham P ^e   Berger, Barry M ^e  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c KAISER PERMANENTE   (United States)

^d MAYO CLINIC   (United States)

^e Exact Sciences Corporation   (United States)

Author keywords

Colorectal neoplasms diagnosis; DNA mutational analysis; DNA neoplasm analysis; Early detection of cancer methods

Indexed keywords

CHST2 PROTEIN; DNA; DTX1 PROTEIN; K RAS PROTEIN; NDRG4 PROYEIN; ONCOPROTEIN; OSTEOGENIN; PARAFFIN; PDGFD PROTEIN; SFMBT2 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VAV3 PROTEIN; BMP3 PROTEIN, HUMAN; GENETIC MARKER; MUSCLE PROTEIN; NDRG4 PROTEIN, HUMAN; NERVE PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER LOCALIZATION; CANCER SCREENING; CANCER TISSUE; COLORECTAL CARCINOMA; CROSS-SECTIONAL STUDY; DNA ISOLATION; DNA METHYLATION; EVALUATION STUDY; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC MARKER; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ASYMPTOMATIC DISEASE; COLORECTAL NEOPLASMS; FECES; GENE EXPRESSION PROFILING; GENETICS; MASS SCREENING; MUTATION; ONCOGENE RAS; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

AGED; ASYMPTOMATIC DISEASES; BIOMARKERS, TUMOR; BONE MORPHOGENETIC PROTEIN 3; COLORECTAL NEOPLASMS; DNA METHYLATION; FECES; FEMALE; GENE EXPRESSION PROFILING; GENES, RAS; GENETIC MARKERS; HUMANS; IMMUNOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; MUSCLE PROTEINS; MUTATION; NERVE TISSUE PROTEINS; PREVALENCE;

EID: 85007545093     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4433-6     Document Type: Article

References (17)

1. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:2564–2575.
2. Benson VS, Atkin WS, Green J, et al. Toward standardizing and reporting colorectal cancer screening indicators on an international level: the international colorectal cancer screening network. Int J Cancer. 2012;130:2961–2973.
3. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–1470.
4. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171.
5. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:659–669.
6. Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol. 2014;27:9–14.
7. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–1297.
8. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–256. quiz e25–e26.
9. Berger BM, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology. 2012;44:80–88.
10. Taylor WR, Kisiel JB, Yab TC, et al. 109 Discovery of nodel DNA methylation markers for the detection of colorectal neoplasia: selection by methylome-wide analysis. Gastroenterology. 2014;146:S-30.
11. Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011;33:101–110.
12. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer. 2009;115:2410–2419.
13. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. Colon and rectum. 7th ed. New York, NY: Springer; 2010.
14. Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11:1313–1318.
15. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164:456–463.
16. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–793.
17. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004;53:1137–1144.